Differential effects of nutritional and non-nutritional therapies on intestinal barrier function in an in vitro model

Journal of Gastroenterology

Volumn 47, Issue 2, 2012, Pages 107-117

  Nahidi, Lily ^a   Day, Andrew S ^a,b   Lemberg, Daniel A ^c   Leach, Steven T ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

Crohn's disease; Hydrocortisone; Infliximab; Intestinal epithelial permeability; Nutritional therapy; Polymeric formula

Indexed keywords

HYDROCORTISONE; INFLIXIMAB; POLYMER; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; MYOSIN II;

ARTICLE; CELL GROWTH; CELL MEMBRANE; CELL STRAIN CACO 2; CONTROLLED STUDY; CROHN DISEASE; DIET THERAPY; DRUG FORMULATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; INTESTINE EPITHELIUM; INTESTINE FUNCTION DISORDER; INTESTINE MUCOSA PERMEABILITY; MONOLAYER CULTURE; MYOSIN II REGULATORY LIGHT CHAIN KINASE GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIGHT JUNCTION; WESTERN BLOTTING; CELL MEMBRANE PERMEABILITY; DRUG EFFECT; IMPEDANCE; INTESTINE MUCOSA; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CROHN DISEASE; ELECTRIC IMPEDANCE; HUMANS; HYDROCORTISONE; INTESTINAL MUCOSA; MYOSIN TYPE II; NUTRITIONAL STATUS; REAL-TIME POLYMERASE CHAIN REACTION; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862331559     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0471-1     Document Type: Article

References (37)

1. Forster C. Tight junctions and the modulation of barrier function in disease. Histochem Cell Biol. 2008;130:55-70.
2. Zeissig S, Burgel N, Gunzel D, Richter J, Mankertz J, Wahnschaffe U, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007;56:61-72. (Pubitemid 46044890)
3. Edelblum KL, Turner JR. The tight junction in inflammatory disease: communication breakdown. Curr Opin Pharmacol. 2009;9:715-20.
4. Day AS, Whitten KE, Sidler M, Lemberg DA. Systematic review: nutritional therapy in paediatric Crohn's disease. Aliment Pharmacol Ther. 2008;27:293-307.
5. de Ridder L, Rings EHHM, Damen GM, Kneepkens CMF, Schweizer JJ, Kokke FTM, et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis. 2008;14:353-8. (Pubitemid 351441324)
6. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med. 2001;135:27-31. (Pubitemid 32619280)
7. Escher JC, Taminiau JAJM, Nieuwenhuis EES, Buller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis. 2003;9:34-58. (Pubitemid 36124247)
8. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024-30. (Pubitemid 47309975)
9. Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744-53. (Pubitemid 43825808)
10. Day AS, Whitten KE, de Jong NSH. Nutrition and nutritional management of Crohn's disease in children and adolescents. Curr Nutr Food Sci. 2006;2:3-14.
11. Berni Canani R, Terrin G, Borrelli O, Romano MT, Manguso F, Coruzzo A, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis. 2006;38:381-7. (Pubitemid 44356207)
12. Fell JM, Paintin M, Arnaud-Battandier F, Beattie RM, Hollis A, Kitching P, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther. 2000;14:281-9. (Pubitemid 30145315)
13. Forster C, Burek M, Romero IA, Weksler B, Couraud PO, Drenckhahn D. Differential effects of hydrocortisone and TNF-alpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol. 2008;586:1937-49. (Pubitemid 351997519)
14. Baldassano R, Braegger CP, Escher JC, Dewoody K, Hendricks DF, Keenan GF, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol. 2003;98:833-8. (Pubitemid 36576310)
15. de Jong NSH, Leach ST, Day AS. Polymeric formula has direct anti-inflammatory effects on enterocytes in an in vitro model of intestinal inflammation. Dig Dis Sci. 2007;52:2029-36. (Pubitemid 47246499)
16. Gaillard JL, Finlay BB. Effect of cell polarization and differentiation on entry of Listeria monocytogenes into the enterocytelike Caco-2 cell line. Infect Immun. 1996;64:1299-308.
17. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol. 2005;166:409-19. (Pubitemid 40189038)
18. Feighery LM, Cochrane SW, Quinn T, Baird AW, O'Toole D, Owens SE, et al. Myosin light chain kinase inhibition: correction of increased intestinal epithelial permeability in vitro. Pharm Res. 2008;25:1377-86.
19. Wroblewski LE, Shen L, Ogden S, Romero-Gallo J, Lapierre LA, Israel DA, et al. Helicobacter pylori dysregulation of gastric epithelial tight junctions by urease-mediated myosin II activation. Gastroenterology. 2009;136:236-46.
20. Fries W, Muja C, Crisafulli C, Cuzzocrea S, Mazzon E. Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies. Am J Physiol Gastrointest Liver Physiol. 2008;294:G938-47. (Pubitemid 351520063)
21. Stevenson BR, Anderson JM, Bullivant S. The epithelial tight junction: structure, function and preliminary biochemical characterization. Mol Cell Biochem. 1988;83:129-45.
22. Gibson PR. Increased gut permeability in Crohn's disease: is TNF the link? Gut. 2004;53:1724-5. (Pubitemid 39556884)
23. Schulzke J-D, Bojarski C, Zeissig S, Heller F, Gitter AH, Fromm M. Disrupted barrier function through epithelial cell apoptosis. Ann N Y Acad Sci. 2006;1072:288-99. (Pubitemid 44448461)
24. Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut. 2004;53:1295-302. (Pubitemid 39120115)
25. Watson AJ, Chu S, Sieck L, Gerasimenko O, Bullen T, Campbell F, et al. Epithelial barrier function in vivo is sustained despite gaps in epithelial layers. Gastroenterology. 2005;129:902-12. (Pubitemid 41242683)
26. Florian P, Schoneberg T, Schulzke JD, Fromm M, Gitter AH. Single-cell epithelial defects close rapidly by an actinomyosin purse string mechanism with functional tight junctions. J Physiol. 2002;545:485-99. (Pubitemid 36004383)
27. Graham WV, Wang F, Clayburgh DR, Cheng JX, Yoon B, Wang Y, et al. Tumor necrosis factor-induced long myosin light chain kinase transcription is regulated by differentiation-dependent signaling events. Characterization of the human long myosin light chain kinase promoter. J Biol Chem. 2006;281:26205-15. (Pubitemid 44401828)
28. Al-Sadi R, Ye D, Dokladny K, Ma TY. Mechanism of Il1β-induced increase in intestinal epithelial tight junction permeability. J Immunol. 2008;180:5653-61.
29. Clayburgh DR, Rosen S, Witkowski ED, Wang F, Blair S, Dudek S, et al. A differentiation-dependent splice variant of myosin light chain kinase, MLCK1, regulates epithelial tight junction permeability. J Biol Chem. 2004;279:55506-13. (Pubitemid 40066552)
30. Weber CR, Turner JR. Inflammatory bowel disease: is it really just another break in the wall? Gut. 2007;56:6-8. (Pubitemid 46044880)
31. Ma TY, Tran D, Hoa N, Nguyen D, Merryfield M, Tarnawski A. Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement. Microsc Res Tech. 2000;51:156-68.
32. Vieira AT, Pinho V, Lepsch LB, Scavone C, Ribeiro IM, Tomassini T, et al. Mechanisms of the anti-inflammatory effects of the natural secosteroids physalins in a model of intestinal ischaemia and reperfusion injury. Br J Pharmacol. 2005;146:244-51. (Pubitemid 43079964)
33. Cury DHB, Costa JE, Irika K, Mijji L, Garcez A, Buchiguel C, et al. Protective effect of octreotide and infliximab in an experimental model of indomethacin-induced inflammatory bowel disease. Dig Dis Sci. 2008;53:2516-20.
34. Zhong Y, Cai D, Cai W, Geng S, Chen L, Han T. Protective effect of galactooligosaccharide-supplemented enteral nutrition on intestinal barrier function in rats with severe acute pancreatitis. Clin Nutr. 2009;28:575-80.
35. Halász J, Holczbauer A, Páska C, Kovács M, Benyó G, Verebély T, et al. Claudin-1 and claudin-2 differentiate fetal and embryonal components in human hepatoblastoma. Hum Pathol. 2006;37: 555-61.
36. Orbán E, Szabó E, Lotz G, Kupcsulik P, Páska C, et al. Different expression of occludin and ZO-1 in primary and metastatic liver tumors. Pathol Oncol Res. 2008;14:299-306.
37. Ma TY, Boivin MA, Ye D, Pedram A, Said HM. Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol. 2005;288: G422-30. (Pubitemid 40261739)